All In Biotech

Drug Trial Radar · NCT05136196

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Dec 6, 2022

Primary completion

Jan 1, 2027

Study completion Jan 1, 2027

Sponsor

Sponsor type
NIH
First posted
Nov 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine how quickly patients can be divided into groups based on biomarkers in their tumors. A biomarker is a biological molecule found in the blood, other body fluids, or in tissues that is a sign of a normal or abnormal process or a sign of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. The two biomarkers that this trial is studying are "tumor mutational burden" and "tumor inflammation signature." Another purpose of this trial is to help doctors learn if cabozantinib and nivolumab shrink or stabilize the cancer, and whether patients respond differently to the combination depending on the status of the biomarkers.

Conditions

  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Locally Recurrent Head and Neck Squamous Cell Carcinoma
  • Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma
  • Locally Recurrent Laryngeal Squamous Cell Carcinoma
  • Locally Recurrent Oral Cavity Squamous Cell Carcinoma
  • Locally Recurrent Oropharyngeal Squamous Cell Carcinoma
  • Metastatic Head and Neck Squamous Cell Carcinoma
  • Metastatic Hypopharyngeal Squamous Cell Carcinoma
  • Metastatic Laryngeal Squamous Cell Carcinoma
  • Metastatic Melanoma
  • Metastatic Oral Cavity Squamous Cell Carcinoma
  • Metastatic Oropharyngeal Squamous Cell Carcinoma
  • Recurrent Melanoma
  • Stage III Hypopharyngeal Carcinoma AJCC v8
  • Stage III Laryngeal Cancer AJCC v8
  • Stage III Lip and Oral Cavity Cancer AJCC v8
  • Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  • Stage IV Hypopharyngeal Carcinoma AJCC v8
  • Stage IV Laryngeal Cancer AJCC v8
  • Stage IV Lip and Oral Cavity Cancer AJCC v8
  • Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  • Unresectable Melanoma

Interventions

  • Biopsy ProcedureProcedure

    Undergo tumor biopsies

  • Biospecimen CollectionProcedure

    Undergo collection of blood samples

  • Cabozantinib S-malateDrug

    Given PO

  • Computed TomographyProcedure

    Undergo CT scans

  • Magnetic Resonance ImagingProcedure

    Undergo MRI scans

  • NivolumabBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Biomarker results turnaround timeTime frame: Up to 21 days
  2. Objective response rateTime frame: At the end of stage I

Locations

233 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona · Recruiting

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Recruiting

  • Tower Cancer Research Foundation

    Beverly Hills, California · Recruiting

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California · Recruiting

  • The Angeles Clinic and Research Institute - West Los Angeles Office

    Los Angeles, California · Recruiting

  • Los Angeles General Medical Center

    Los Angeles, California · Recruiting

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • Rocky Mountain Regional VA Medical Center

    Aurora, Colorado · Active not recruiting

  • UCHealth Memorial Hospital Central

    Colorado Springs, Colorado · Recruiting

  • Memorial Hospital North

    Colorado Springs, Colorado · Recruiting

  • Poudre Valley Hospital

    Fort Collins, Colorado · Recruiting

  • Cancer Care and Hematology-Fort Collins

    Fort Collins, Colorado · Recruiting

  • UCHealth Greeley Hospital

    Greeley, Colorado · Recruiting

  • Medical Center of the Rockies

    Loveland, Colorado · Recruiting

  • Helen F Graham Cancer Center

    Newark, Delaware · Recruiting

  • Medical Oncology Hematology Consultants PA

    Newark, Delaware · Recruiting

  • Mayo Clinic in Florida

    Jacksonville, Florida · Recruiting

  • AdventHealth Orlando

    Orlando, Florida · Recruiting

  • Hawaii Cancer Care - Westridge

    ‘Aiea, Hawaii · Suspended

  • Hawaii Cancer Care Inc - Waterfront Plaza

    Honolulu, Hawaii · Suspended

  • Queen's Cancer Cenrer - POB I

    Honolulu, Hawaii · Suspended

  • Queen's Medical Center

    Honolulu, Hawaii · Suspended

  • Queen's Cancer Center - Kuakini

    Honolulu, Hawaii · Suspended

  • Saint Alphonsus Cancer Care Center-Boise

    Boise, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Boise

    Boise, Idaho · Recruiting

  • Saint Alphonsus Cancer Care Center-Caldwell

    Caldwell, Idaho · Recruiting

  • Kootenai Health - Coeur d'Alene

    Coeur d'Alene, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Fruitland

    Fruitland, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Meridian

    Meridian, Idaho · Recruiting

  • Saint Alphonsus Cancer Care Center-Nampa

    Nampa, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Nampa

    Nampa, Idaho · Recruiting

  • Kootenai Clinic Cancer Services - Post Falls

    Post Falls, Idaho · Recruiting

  • Kootenai Clinic Cancer Services - Sandpoint

    Sandpoint, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Twin Falls

    Twin Falls, Idaho · Recruiting

  • Rush-Copley Medical Center

    Aurora, Illinois · Suspended

  • Illinois CancerCare-Bloomington

    Bloomington, Illinois · Recruiting

  • Illinois CancerCare-Canton

    Canton, Illinois · Recruiting

  • Illinois CancerCare-Carthage

    Carthage, Illinois · Recruiting

Showing 40 of 233 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.